| Today’s Big NewsJul 7, 2025 |
| By Nick Paul Taylor Chugai Pharmaceutical has teamed up with Gero, offering up to $250 million for the chance to develop antibodies against age-related disease targets identified by its partner's AI-driven platform. |
|
|
|
By James Waldron Jasper Therapeutics is blaming a dud batch of its urticaria drug for derailing a phase 1/2 study of the candidate and raising the possibility of a restructuring to conserve cash. |
By Nick Paul Taylor A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval for a potential rival to Blueprint Medicines’ Ayvakit. |
Sponsored by SAP and Answerthink Leaders discuss how built-in best practices and automation streamline growth for lean life sciences teams |
|
| Is your process truly scalable, efficient and validation-ready?Can your supply chain and manufacturing scale flex as your needs evolve?Do you have the manufacturing capacity to deliver when demand takes off? Speak with Lonza’s experts and get answers that drive smarter decisions today.
|
|
By Angus Liu After several PD-1xVEGF competitors forged alliances with Big Pharma players, Summit Therapeutics, the frontrunner in this hot cancer drug field, is reportedly seeking its own deal. |
By James Waldron Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main goal of a phase 2 trial. |
By James Waldron 4D Molecular Therapeutics laid off a quarter of its workforce last month with early-stage R&D bearing the brunt of the changes. |
By Fraiser Kansteiner The FDA has approved sebetralstat under the brand name Ekterly as a new, oral treatment option for acute attacks of hereditary angioedema (HAE) in adults and children ages 12 years and older. The nod came just a few short weeks after the agency missed its June 17 target date originally established for the decision. |
By Darren Incorvaia A group of 53 biotech leaders is expressing support for mifepristone in a letter to the FDA, urging the agency not to impose new restrictions on its use as an abortion medication and slamming a "fatally flawed" report cited as reasoning for the potential limitations. |
By Gabrielle Masson Fierce 15 nominations are open! We're searching for the most innovative, resourceful and visionary biotechs leading the way through the industry's mercurial conditions. |
By Darren Incorvaia Inhibiting an overabundant enzyme saved a key component of a brain signaling pathway that is vital for motor control in a new mouse study, bolstering the prospects for the biotechs currently targeting the enzyme as a treatment for Parkinson’s disease. |
By Dave Muoio The so-called “big, beautiful bill” fulfills several of Trump’s campaign promises to cut taxes, but will add trillions to the national debt and is opposed by the healthcare industry for cuts to funding and coverage. |
Fierce podcastsDon’t miss an episode |
| | In this episode of "The Top Line," Teva CEO Richard Francis shares progress on the company’s “Pivot to Growth” strategy and what lies ahead. |
|
|---|
|
|
|
Thursday, July 22, 2025 | 10am ET / 7am PT Join us to take an exciting look at the forefront of REMS transformation. Learn how leading technology, integrated strategies and operational excellence are redefining what’s possible. Gain the insights you need to reduce complexity, enhance compliance and deliver more value across the REMS lifecycle. Register now.
|
|
| WhitepaperThis white paper outlines how we apply industry-backed practices and proprietary technologies to proactively safeguard sterility and performance. Sponsored by: Lonza |
| WhitepaperPresented by Blue Matter, strategic consultants in the life sciences Sponsored by Blue Matter Consulting |
| Executive SummaryBiotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster. Sponsored by: IQVIA Laboratories |
| |
|
